Cargando…
Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and the long-term survival varies with different ages. We performed a retrospective analysis of 122 newly diagnosed adults with standard-risk ALL treated with Escherichia coli asparaginase (E. coli-asparaginase, n = 50) and polyethylene...
Autores principales: | Liu, Wen-jian, Wang, Hua, Wang, Wei-da, Zhu, Meng-yuan, Liu, Cheng-cheng, Wang, Jing-hua, Lu, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175128/ https://www.ncbi.nlm.nih.gov/pubmed/28000713 http://dx.doi.org/10.1038/srep39463 |
Ejemplares similares
-
PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020) -
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017) -
Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis
por: Dai, Zhan-Jing, et al.
Publicado: (2021) -
A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia
por: Liang, Jiabao, et al.
Publicado: (2018) -
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)